tisagenlecleucel 与 axicabtagene ciloleucel 在成人 r/r 滤泡性淋巴瘤中的疗效和安全性比较

Regulatory approvals of tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel) have established the feasibility of chimeric antigen receptor T-cell therapies for the treatment of adults with relapsed or refractory follicular lymphoma (r/r FL).

This study used individual patient data from ELARA (tisa-cel) and aggregate published patient data from ZUMA-5 (axi-cel) to compare efficacy and safety outcomes in r/r FL using matching-adjusted indirect comparison methods. After adjustment for baseline differences in the trial populations, the results suggested that tisa-cel ( n = 52), compared with axi-cel ( n = 86), had similar effects on overall response rate (91.

2% vs. 94. 2%; p = . 58), complete response rate (74. 0% vs. 79. 1%; p = . 60), progression-free survival (HR [95% CI]: 0. 8 [0. 4, 1. 9]; p = . 67), and overall survival (HR [95% CI]: 0. 5 [0. 2, 1. 5]; p = . 21). Tisa-cel ( n = 53) was associated with better safety outcomes than axi-cel ( n = 124), reflected by lower rates of any grade and grade ≥3 cytokine release syndrome and neurological events.